CSF3 and plasma cell myeloma: Clinical trials with BL-8040 and G-CSF (a glycoprotein that induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4) [74] have shown a significant increase in CD34+ cell mobilization from the bone marrow for patients that require autologous transplant in myeloma [75].